Industry analysts covering digital health, health IT, and biotech commercial performance shape how hospitals, payers, and investors evaluate you before a sales conversation ever starts. We build the briefing cadence and evidence base that gets you covered accurately, and cited.
The Problem
Nobody owns the relationship until a report is already being written
Most biotech and pharma companies engage analysts reactively, when a research firm reaches out for an upcoming report, rather than proactively building the relationship between cycles. By the time an inquiry lands, the analyst has already formed a working view from competitors who briefed months earlier, and a single rushed briefing rarely shifts a perspective that's had a head start.
Briefings lean on clinical claims when analysts need commercial and operational evidence
Analysts covering digital health, health IT, and biotech commercial performance – firms like KLAS Research, Gartner Healthcare, Frost & Sullivan, or EvaluatePharma-tier research – are evaluating deployment success, customer satisfaction, and market execution, not just clinical efficacy. A briefing built entirely around trial data or mechanism of action misses what these analysts actually need to write a credible, differentiated assessment.
No one tracks which categories and reports actually influence your buyers
Health systems, payers, and institutional investors reference different research depending on the decision – KLAS for deployed health IT performance, EvaluatePharma for pipeline and commercial forecasting, category-specific analyst notes for competitive positioning. Without mapping which specific reports your actual buyers and investors read, analyst relations effort spreads across coverage that doesn't move the decisions that matter.
Competitive and market intelligence from inquiries never makes it back to commercial strategy
Analyst inquiries and RFI questionnaires are one of the richest sources of structured competitive intelligence available, since analysts are actively comparing you against named competitors on specific criteria. Most companies treat inquiry response as a one-off compliance task instead of feeding what's learned back into positioning, product roadmap conversations, and sales enablement.
How We Help
We start by mapping which analyst firms and specific reports your actual buyers, payers, and investors reference for decisions in your category – KLAS for deployed health IT performance, Gartner Healthcare or Forrester for broader digital health categorization, EvaluatePharma or Frost & Sullivan-tier research for pipeline and commercial forecasting – so effort concentrates on coverage that actually influences a decision instead of chasing every firm that will take a briefing.
From there we build a proactive briefing cadence instead of a reactive one. That means initiating relationships with priority analysts between research cycles, not waiting for an inquiry, so your evidence and positioning are already part of an analyst's working view before they start drafting the next report. Briefings get built around what these analysts actually need – deployment outcomes, customer satisfaction data, market execution evidence – alongside clinical substance, translated for an audience evaluating commercial credibility, not reviewing a scientific poster.
We manage the full inquiry and RFI pipeline as it comes in, coordinating responses across product, medical affairs, and commercial so analysts get consistent, substantiated answers instead of whoever happens to be available that week. Every inquiry and briefing gets debriefed internally, and what's learned – competitive comparisons, category definition shifts, gaps analysts flag – feeds back into positioning and sales enablement instead of disappearing into a single response document.
We track category evolution actively, since digital health and biotech categories get redrawn by analyst firms every research cycle as new subcategories emerge. Early engagement on how a category gets defined is one of the highest-leverage moves available, and companies that show up after a category framework is published inherit someone else's definition of what they do.
What we deliver
- Analyst and report mapping – prioritized list of firms and specific reports your actual buyers and investors reference
- Proactive briefing program – a recurring cadence that builds analyst relationships between research cycles, not just during them
- Inquiry and RFI pipeline management – coordinated, substantiated responses across product, medical affairs, and commercial
- Competitive intelligence feedback loop – insights from analyst engagement fed back into positioning and sales enablement
By the time an analyst inquiry lands in your inbox, the report is often already being shaped by competitors who briefed months earlier. Analyst relations that starts at the inquiry is analyst relations that's already behind.
Our Methodology
We run this as a 90-day sprint built around the two failures that leave most biotech and pharma companies under-covered or miscategorized: reactive engagement that starts too late in the research cycle, and briefings built around clinical claims when analysts need commercial and operational evidence. The first 30 days are diagnostic – mapping which analyst firms and reports your buyers and investors actually reference, auditing current or past briefing materials, and identifying priority analysts to engage proactively. Days 30 to 60 build the briefing program and inquiry management process, coordinating evidence and messaging across product, medical affairs, and commercial. The final 30 days launch proactive briefings with priority analysts and stand up the feedback loop that routes what's learned back into positioning.
What separates this from a standard PR or comms function handling analyst relations as a side responsibility is that most companies without a dedicated program only engage analysts reactively, when an inquiry forces the issue, and briefings default to the clinical narrative the team is most comfortable presenting. We build proactive relationships and commercial evidence into the program from the start, because for most biotech and pharma companies the gap isn't a weak product story – it's that analysts never hear the commercial and operational version of it until it's too late to shape the report.
How We Work
The first 30 days are audit and mapping. We identify which analyst firms and reports matter most to your buyers and investors, review any past briefing materials or inquiry responses, and flag priority analysts for proactive outreach. Days 30 through 60 build the briefing program – message development coordinated across product, medical affairs, and commercial, and a process for managing inbound inquiries consistently. By day 90 we're running proactive briefings and feeding competitive intelligence back into your positioning work.
On our side, the team is an analyst relations lead who owns the briefing cadence and inquiry pipeline, coordinating directly with your product, medical affairs, and commercial leadership rather than operating as an isolated comms function. From your side, we need subject matter experts available for briefing calls, medical and legal review capacity for any clinical claims used in analyst materials, and a point of contact who can turn around RFI responses on the analyst firm's timeline, which is often tight.
Cadence is weekly during the first 90 days, covering mapping progress, briefing material development, and inquiry pipeline status, with async coordination as inquiries land on their own schedule. After the initial sprint, most engagements move to a monthly cadence tied to the analyst research calendar, with intensified activity around major report cycles. Typical engagement length is 6 to 12 months to build real coverage history, with many companies continuing on an ongoing retainer since analyst relationships require sustained maintenance.
What to expect at each phase: month one clarifies which coverage actually matters to your buyers, often narrower than assumed. Month two shows the briefing program and inquiry process taking shape. Month three onward is where proactive relationships start showing up as improved report positioning and faster analyst responsiveness to inquiries.
- Proactive relationships with the analyst firms your buyers and investors actually reference
- More accurate and favorable category positioning in analyst reports
- Coordinated, substantiated inquiry and RFI responses across functions
- Competitive intelligence from analyst engagement feeding into commercial strategy
If your biotech & pharma company needs analyst relations leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does an analyst relations engagement cost for a biotech or pharma company?
Most engagements with us run $8K-18K monthly, depending on the number of priority analyst firms and the coordination complexity across product, medical affairs, and commercial. That's typically less than the cost of a dedicated in-house analyst relations hire, and it includes the cross-functional coordination that role would otherwise require on its own. Companies with broader coverage needs across multiple categories sit toward the higher end.
How long before we see results from an analyst relations engagement?
Analyst mapping and initial briefing materials are typically ready within the first 30-45 days. Because analyst research cycles run on their own calendar, meaningful coverage changes – inclusion in a report, improved category positioning – typically show up over one to two research cycles, often 6-12 months. Faster wins include improved inquiry response quality and analyst responsiveness within the first 90 days.
How does the analyst relations team integrate with our existing staff?
We coordinate directly across your product, medical affairs, and commercial teams to build briefing materials and manage inquiries, rather than operating as an isolated function. Weekly working sessions during buildout cover briefing development and inquiry status with whoever owns commercial or comms strategy. If you have an in-house AR function, we become the proactive program management and cross-functional coordination layer.
What makes Winston Francois different from a traditional PR or AR agency?
Most PR agencies handle analyst relations reactively as a side function of press outreach, responding to inquiries as they land rather than building relationships proactively between research cycles. We build a dedicated proactive briefing program and coordinate the commercial and operational evidence analysts actually need, not just clinical claims. We operate as an embedded team accountable to coverage quality, not inquiry response volume.
How do you measure ROI from an analyst relations engagement?
We track briefing frequency and proactive engagement with priority analysts, accuracy and favorability of category placement in published reports, and inquiry response quality and turnaround time. Where analyst coverage cites specific evidence you provided, that's a direct signal the engagement is working. We also track whether competitive intelligence from analyst inquiries is actually feeding into positioning decisions.
What type of biotech or pharma company is the right fit for this service?
Companies selling into health systems, payers, or institutional investors where analyst research firms like KLAS, Gartner Healthcare, or EvaluatePharma-tier coverage genuinely influence buyer and investor decisions are the best fit. Companies in a category still being defined by analyst firms, where early engagement can shape the framework, tend to see the highest-leverage impact. The first step is mapping which specific analyst coverage your buyers actually reference.
